CytoMed Therapeutics Limited
GDTCNASDAQHealthcareBiotechnology
Previous close
$1.03
+$0.131 · +14.57%
GDTC company overview
Historical prices · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
42
Fair Value
Momentum
37
Weakening
Sentiment
51
Mixed
Risk resilience
31
High Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteCytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- SG
- CEO
- Chee Kong Choo
- Listed since
- Apr 14, 2023
- Employees
- 42
Market position
Day range
Current $1.03
52-week range
Current $1.03
- Open
- $0.8559
- Previous close
- $0.899
- Volume
- 54.49K
- 0.88× average
- Average volume
- 61.84K
- Average daily volume
- Market cap
- 12.19M USD
- Beta
- 0.05
- Market reference 1
- 50-day average
- $0.9645
- +6.79% above average
- 200-day average
- $1.1657
- -11.64% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- P/E (TTM)
- -3.23×
- P/B (TTM)
- 2.36×
- P/S (TTM)
- 24.08×
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- -20.48%
- Operating margin
- -672.18%
- Net margin
- -754.66%
Financial health
- Debt / equity
- 0.07×
- Altman Z-score
- 3.08
- Piotroski F-score
- 2 of 9
Earnings
- EPS beat rate
- 0%
- 0 beats, 3 misses, 0 met estimates
- Average EPS surprise
- -89.22%
- 3 comparable reports
- Latest EPS result
- -0.11
EPS: actual versus estimate
Recent quarterly results
Revenue: actual versus estimate
Recent quarterly results
GDTC peers
Continue in GoAI
Research GDTCresearch.disclaimer